TRIAL DETAIL

Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma

Drug:
Trial Name:
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date 11/01/2011
Age of Trial (yrs) 10.7
Treatment Phase:
Gleevec-resistant
Drug Category:
AKT inhibitor
Strategy:
Block AKT
Trial Type:
GIST not specified. GIST patient enrollment unknown.
Other Protocol IDs:
ARQ 092-101
Sponsor:
ArQule
Patient Contact:
ArQule, Inc 781-994-0300 ClinicalTrials@arqule.com
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:
Purpose
This is an open-label, Phase 1, dose escalation study of oral ARQ 092 administered to subjects with advanced solid tumors and recurrent malignant lymphoma. The study is designed to explore the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARQ 092 and to define a recommended Phase 2 dose of ARQ 092.

Trial Links

Trial Results

Drug Information

ArQule website
 

Trial Sites

Name
Address
City
State
Zip
Country
1475 Northwest 12th Ave
Miami
FL
33136
USA
10460 N. 92nd St.
Scottsdale
AZ
85258
USA
1365C Clifton Road
Atlanta
GA
30322
USA
4319 Medical Dr.
San Antonio
TX
78229
USA
Lafayette
IN
47905
USA
Atlanta
GA
30341
USA